Fixed-ratio combination of basal insulin glargine 100 U/ml with GLP1-receptor agonist lixisenatide: clinical trials and their implications in clinical practice

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: SchronerMED s. r. o., Košice
Published in: Diab Obez 2019; 19(38): 115-117
Category: Clinical studies

Overview

In July 2019 came to clinical practice fixed – ratio combination of basal insulin glargine and GLP-1 receptor agonist lixisenatide (iGlarLixi). Clinical studies prove efficacy and safety of this fixed-ratio combination. Each component of the iGlarLixi contributes to improvement of glycaemic compensation, while reducing the side effects associated with the individual components (hypoglycaemia, gastrointestinal adverse effects, weight gain). Coming of combination iGlarLixi significantly increased possibilities of simple intensification of type 2 diabetes therapy in patients inadequately compensated on basal insulin with/without OAD.

Keywords:

efficacy – fixed-ratio combination – glargine 100 U/ml – lixisenatide – Safety

Sources

Adamíková A. Suliqua a její použití v širokém spektru pacientu s diabetes mellitus 2. typu. Acta Medicinae 2019; 8(3): 104–106.
Davies MJ, Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI: <https://doi.org/10.1007/s00125–018–4729–5>.
Aroda VR, Rosenstock J, Wysham C et al. Efficacy and safety of LixiLan, a titrable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 inadequately controlled on basal insulin and metformin. The LIxiLan-L ramdomizet trial. Diabetes Care 2016; 39(11): 1972–1980. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–1495>. Erratum in Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016; 39: 1972–1980. [Diabetes Care 2017].
Blonde L, Barard L, Saremi A et.al. Impact of type 2 diabetes duration on response to iGlarLixi: a subanalysis of LixiLan-L. EASD 2018; P 787. Diabetes 2018; 67(Supplement 1). Dostupné z DOI: <https://doi.org/10.2337/db18–1094-P>.
Giorgino F, Retnakaran R, Vidal J. iGlarLixi effectively reduces residual hyperglycemia in patients with type 2 diabetes on basal insulin: a post hoc analysis from the Lixi-Lan study. ADA 2018; P 1095. Diabetes 2018; 67(Supplement 1). Dostupné z DOI: <https://doi.org/10.2337/db18–1095-P>.
Meier J, Anderson J, Wysham C et al. Propensity score matched patient-level comparison of iGlarLixi and basal/bolus regimen in patients with type 2 diabetes. EASD 2018; P 786. Diabetes 2018; 67(Supplement 1). Dostupné z DOI: <https://doi.org/10.2337/db18–1094-P>.
Sayre T, Shan R, Thomas J et.al. Network meta-analysis if iGlarLixi, a fixed-ratio combination GLP-1 RA and basal insulin versus insulin premix. IDF 2017; P-0354. Dostupné z WWW: <https://drevidence.com/network-meta-analysis-of-iglarlixi-a-fixed-ratio-combination-glp-1-ra-and-basal-insulin-versus-insulin-premix/>.
Súhrn charakteristických vlastností lieku iGlar/lixi (Suliqua ®). Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/suliqua-epar-product-information_sk.pdf>.